European Commission approves Trodelvy to treat unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer patients who have received endocrine-based therapy – Gilead Sciences

Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The approval by the European Commission follows the positive opinion of the […]

New ACR Breast Cancer Screening Guidelines call for earlier and more-intensive screening for high-risk women

New American College of Radiology® (ACR®) breast cancer screening guidelines now call for all women — particularly Black and Ashkenazi Jewish women — to have risk assessment by age 25 to determine if screening earlier than age 40 is needed. The ACR continues to recommend annual screening starting at age 40 for women of average risk, but earlier and more intensive screening for high-risk patients. The new […]

Female healthworkers need better radiation protection to minimise breast cancer risk

Women working in healthcare who are regularly exposed to radiation from x-rays and other imaging procedures need better ionising radiation protection to help minimise their risk of developing breast cancer, argue doctors in The BMJ today. Ionising radiation is a known human carcinogen and breast tissue is highly radiation sensitive. As such, there are concerns that regular exposure to ionising radiation during image guided […]

Breast cancer survivorship doubles

It was the information she couldn’t find that led Amy Kirkham, an assistant professor in the University of Toronto’s Faculty of Kinesiology & Physical Education (KPE), to her latest discovery. Asked by the Canadian Women’s Heart Health Alliance to co-author a scientific statement paper in 2020 on the state of women’s heart health in Canada, Kirkham — whose research is […]

Study finds COVID-19 pandemic reduced breast, cervical, colorectal cancer screenings by millions

New findings led by researchers at the American Cancer Society (ACS) show the number of women in the United States who reported having a recent (in the past year) breast cancer or cervical cancer screening dropped by 2.13 million (6%) and 4.47 million (11%) respectively in 2020 compared to 2018. The study is the first of its kind to evaluate the impact of […]

Half of all women experience false positive mammograms after 10 years of annual screening

A study led by UC Davis Health has found that half of all women will experience at least one false positive mammogram over a decade of annual breast cancer screening with digital breast tomosynthesis (3D mammography). The risk of false positive results after 10 years of screening is considerably lower in women screened every other year. A false positive is when […]

Updated results from pivotal HER2CLIMB trial evaluating Tukysa in patients with HER2-positive breast cancer – Seagen Inc

Seagen Inc. announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional 15.6 months of follow-up when Tukysa (tucatinib) was combined with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases. The data were featured […]

Phase III monarchE trial of Verzenio in breast cancer published in Annals of Oncology – Eli Lilly

Eli Lilly announced updated data from the positive Phase III monarchE trial evaluating the investigational use of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC). As previously published in the Journal of Clinical Oncology, monarchE met its […]

Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer – AstraZeneca + Daiichi Sankyo

Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients. DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based regimens. Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial […]

SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients – MacroGenics

MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS analysis of the SOPHIA study was performed after 385 OS events occurred in the intent-to-treat (ITT) population. As per the study protocol, OS was defined as the number of days from randomization […]